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Abstract
Although it is estimated that COVID-19 life-threatening conditions may be diagnosed in less than 1:1000 infected individuals
below the age of 50, but the real impact of this pandemic on pediatric patients with different types of primary immunodeficiency
(PID) is not elucidated. The current prospective study on a national registry of PID patients showed that with only 1.23 folds
higher incidence of infections, these patients present a 10-folds higher mortality rate compared to population mainly in patients
with combined immunodeficiency and immune dysregulation. Therefore, further management modalities against COVID-19
should be considered to improve the survival rate in these two PID entities using hematopoietic stem cell transplantation and
immunomodulatory agents.
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Introduction
The novel coronavirus disease, known as coronavirus disease
2019 (COVID-19), is an acute infectious respiratory disease
that first emerged in Wuhan, China, in late 2019 and is char-
acterized as a pandemic in mid-March 2020 by World Health
Organization [1]. It has been found that COVID-19 causes
severe acute respiratory syndrome (SARS, therefore coined
as SARS-CoV-2) similar to two other RNA viruses from the
Coronoviridea family SARS-CoV-1 and Middle East
respiratory syndrome coronavirus (MERS-CoV). SARS-
CoV-2 main route of entry to a human host is the
angiotensin-converting enzyme 2 (ACE2) receptor. ACE2 re-
ceptor is ubiquitously expressed on the surfaces of various cell
types, including cells of the airway epithelium which is the
major site of infection [2]. Besides the ACE2 receptor, SARS-
CoV-2 uses the transmembrane serine protease 2
(TMPRSS2), a cellular serine protease, for the host cell entry,
which activates the SARS-CoV-2 spike protein by cleaving
the Furin site at the S1/S2 subunits [3, 4]. Upon entry, the
virus can subsequently affect endosomes, and eventually, fuse
viral and lysosomal membranes [5]. Coronaviruses are
pathogens affecting both humans and animals; particularly
SARS-CoV-2 is highly contagious and can be transmitted
directly through respiratory droplets often even before the
infected person shows symptoms or indirectly by touching
infected surfaces and following inoculation within mucosal
layers [2, 6].
SARS-CoV-2 infection results in the development of an
unusual form of pneumonia and can cause acute respiratory
distress syndrome (ARDS) [7]. More than 35 million infected
cases were diagnosed worldwide, with a mortality rate of 4%
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(1–20%) and about 20% of those who get COVID-19 become
seriously ill and require oxygen, with 5% becoming critically
ill and needing intensive care (https://www.who.int/
emergencies/diseases/novel-coronavirus-2019/question-and-
answers-hub/q-a-detail/coronavirus-disease-covid-19),
mainly in old patients with multiple comorbidities. Of note, it
is estimated that life-threatening conditions may be observed
in less than 1:1000 infected individuals below the age of 50
[7], suggesting some underlying susceptibility factors in this
selected group of patients. Hence, it is expected to see severe
COVID-19 cases in individuals with primary immunodefi-
ciencies (PIDs). Due to poor cellular immunity and viral con-
trol, disease severity is expected to be higher in combined
immunodeficiencies than patients with humoral defects.
Patients with immune dysregulation may also be vulnerable
to the disease because of the risk of an adverse unregulated
inflammatory response in these patients. Noteworthy, patients
with defects in their innate immune system, especially those
with defects in the interferon (IFN) pathway, seem to face
more frequently a critical course of the disease [8]. PID prev-
alence (range 1:8500–1:100000 for symptomatic patients) and
the proportion of PID entities (more than 400 heterogeneous
defects) in each country may impact the number of patients at
risk due to COVID-19. Recent discoveries identified the role
of defective immune-related genes involved in RNA-virus
infection susceptibilities with a critical function in IFN path-
ways including IFN receptors (IFNAR1 and IFNAR2), signal
transducer and activator of transcription of IFN (STAT1 and
STAT2), IFN regulatory factors (IRF7, IRF9, and IFIH1), and
RNA polymerase III (POLR3A, POLR3C, and POLR3F) [9].
To investigate this hypothesis, we conducted a prospective
study to compare the rate and outcomes of COVID-19 infec-
tion between diagnosed cases in the Iranian PID registry with
population-based data.
Methods
Iranian Primary Immunodeficiency Registry (IPIDR)
This study was conducted as a cohort of patients, prospective-
ly enrolled in the IPIDR from the “National PID Network”
[10]. The IPIDR is managed by the Research Center for
Immunodeficiencies (Tehran, Iran) and its main aim is to pro-
vide epidemiological, clinical, and molecular data of PID in
Iran. By the latest estimation in 2020, Iran has a population of
84,012,442 citizens (with an average annual birth rate of
1,300,000) and according to the age structure, 23.7% are less
than 14 years old. Data on COVID-19 infection in PID pa-
tients were compared with the normal population (471,772
patients, incidence of 2036 cases per day, 26,957 total death,
https://www.worldometers.info/coronavirus/, reported from
Iranian Ministry of Health, Tehran, Iran, access data 4
October 2020). This study received approval from the Ethics
Committee of the Tehran University of Medical Science.
Moreover, written informed consent has been obtained from
all patients, their parents, or legal guardians.
The registry database is hosted in the Children’s Medical
Center (Tehran, Iran) which serves as a referral hospital for
suspected or diagnosed PID cases. Moreover, 38 medical cen-
ters, affiliated to 27 medical science universities, collaborated
in the registry program from the major provinces of the coun-
try to form the PID network. All participating centers had
access to national guidelines [11] and necessary laboratory
equipment for clinical and immunological evaluations [10].
Subsequently, cases with a suspected diagnosis were referred
and re-evaluated in the Children’s Medical Center for a defin-
itive diagnosis.
Clinical and Immunologic Diagnoses in COVID-19-
Infected PID Patients
The clinical diagnosis of the PID patients was made according
to the criteria of the European Society for immunodeficiencies
(ESID) [12]. A questionnaire surveyed the patients’ demo-
graphic information, age of disease onset, age of diagnosis,
family history, a detailed clinical history that included vacci-
nation history and associated adverse reactions, recurrent in-
fections, physical examination findings, laboratory data, and
treatment history. Secondary defects of the immune system,
including those caused by human immunodeficiency virus
(HIV) were ruled out. Laboratory evaluations were performed
in the study group as indicated, including complete blood and
differential counts, serum protein profile and immunoglobulin
levels, serum IgG subclass levels, isohemagglutinin titers,
specific antibody responses, disease-specific autoantibody
measurements, flow cytometric evaluation of lymphocyte
subsets, nitro blue tetrazolium dye/dihydrorhodamine test,
granulocyte function and chemotaxis tests, lymphocyte trans-
formation and T cell function tests, radiosensitivity, measure-
ment of complement component levels, and hemolytic com-
plement activity [10]. Microbiological, pathological and im-
aging evaluations were performed for clinical diagnosis when
required. A computerized database program (new registry sec-
tion in http://rcid.tums.ac.ir/, access data 4 October 2020) was
implemented for data entry. After reviewing the cases by the
administrator of the system for duplicated cases, patients with
incomplete diagnostic criteria were excluded. The online
database was updated frequently for approved patients and
all follow-up data sent by the end of the study period were
included. If the diagnosis of PID were confirmed before the
time of COVID-19 patients, following evaluation were per-
formed including new clinical presentation, high-resolution
computed tomography (HRCT), and reverse transcriptase-
polymerase chain reactions (RT-PCR) as well as complete
blood count (CBC), C-reactive protein (CRP), and erythrocyte
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sedimentation rate (ESR). For patients with a recent diagnosis
of PID, a comprehensive questionnaire was provided and
filled out for each patient which consists of demographical
data, clinical manifestations related to their PID and
COVID-19, laboratory tests findings such covering both PID
and COVID-19 diagnoses confirmation. Furthermore, the
type of treatment and outcome were also provided for each
patient.
Genetic Analysis and Diagnoses in COVID-19-Infected
PID Patients
Genomic DNA was extracted from whole blood from patients
who agreed with genetic tests and for patients with classical
clinical presentations suggestive of a specific PID, targeted
sequencing was performed (Table S1). For patients in whom
targeted sequencing failed or who had a clinical presentation
resembling several genetic defects, whole-exome sequencing
was performed to detect single nucleotide variants, insertion/
deletions, and large deletions using a pipeline described pre-
viously [13, 14]. Candidate variants were evaluated by the
Combined Annotation Dependent Depletion (CADD) algo-
rithm and an individual gene cutoff given by using the
Mutation Significance Cutoff (MSC) was considered for im-
pact predictions [15]. The Gene Damage Index (GDI) server
and the Human Gene Connectome (HGC) were used to mak-
ing a combined effect prediction [15]. The pathogenicity of all
disease attributable gene variants was re-evaluated using the
updated guideline for interpretation of molecular sequencing
by the American College of Medical Genetics and Genomics
criteria [16, 17], considering the allele frequency in the popu-
lation database, computational data, immunological data, fa-
milial segregation and parental data (confirmatory Sanger se-
quencing for probands and their parents), and clinical
phenotyping.
Classification of COVID-19-Infected PID Patients
After confirmation of their clinical and genetic diagnosis,
patients were classified according to the International
Union of Immunological Societies (IUIS) updated classi-
fication including 9 categories of immunodeficiencies af-
fecting cellular and humoral immunity (non-syndromic
combined immunodeficiency or CID), combined immuno-
deficiencies with associated or syndromic features
(syndromic CID), predominantly antibody deficiencies
(PAD), diseases of immune dysregulation, congenital de-
fects of phagocyte number or function (phagocytic disor-
ders), autoinflammatory disorders, defects in intrinsic and
innate immunity , complement def ic iencies , and
phenocopies of inborn errors of immunity [9].
Results
Among 4718 registered patients, 2754 patients (998 females,
median age 108months) were alive and onmonthly follow-up
(58.3%, before the emergence of COVID-19 first report in the
country 19 February 2020). During this period, each patient
had on average 8 follow-up visits in our peripheral centers,
and the COVID-19 test was performed in patients with the
clinical triad of cough, fever, and dyspnea. To date, 19 patients
(7 females, median age 106 months) were confirmed with
positive reverse transcriptase-polymerase chain reactions
(RT-PCR) SARS-CoV-2 test (1:144 incidence compared to
1:178 in the total population, 1.23 folds higher risk of infec-
tions). It seems that this measurement is underestimated since
PID patients/families were trained for tight isolation compared
to other immunocompetent individuals in the population.
Exposure to SARS-CoV-2 from an unknown source or a
source outside the child’s family accounted for 84.2% of the
cases of infection (15.8% of PID patients have a medical his-
tory of exposure to another COVID-19-infected family mem-
bers prior to their hospital admission). Detailed comparison of
infection rates between PID patients versus the total popula-
tion based on adjusted age-groups is shown in Fig. S1.
Combined immunodeficiencies (n = 10, all without hema-
topoietic stem cell transplantation or HSCT, 47.0%) were the
major PID entity among COVID-19 positive cases followed
by humoral immunodeficiencies (n = 4), phagocytic defects
(n = 2), immune dysregulation (n = 2), and autoinflammatory
disorders (n = 1, Table 1). Of note, no COVID-19 infection
was observed in patients with innate or complement deficien-
cies (117 and 85 total registered alive patients, respectively).
COVID-19 infections alone or in complex with other mani-
festations were the first clinical presentation of PID in 4 pa-
tients, mainly combined immunodeficiencies (Tables 2 and 3).
Current genetic data on the evaluated patients is indicated in
Fig. S2. Of note, COVID-19 infection was not yet reported in
any of the alive patients with a defect in the IFN pathway (n =
23, data not shown). The geographical distribution of identi-
fied patients matched with the cumulative incidence of PID,
but not with the incidence of COVID-19 in the general popu-
lation (Fig. S3).
Details of clinical manifestations and laboratory findings of
patients before and after SARS-CoV-2 infections are summa-
rized in Tables 2 and 3, S2 and S3. The majority of patients
had a history of lower respiratory tract infection before
COVID-19 (89.4%, except for two patients with STK4 and
IL1RN deficiencies). Severe distress requiring respiratory
support was documented as COVID-19 features in 10 patients
from which 7 had lymphoproliferation (70%) including
lymphadenopathy, hepatosplenomegaly, and non-necrotizing
granulomatous inflammation. Moreover, bronchiectasis
(21.0%), cardiovascular complications (10.5%), and liver fail-
ure (10.5%) were observed in patients with poor prognosis. Of
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note, bone marrow analysis and laboratory data of COVID-
19-infected patients with immune dysregulation (P15 and
P16) did not reveal hemophagocytic lymphohistiocytosis
(HLH) activity at the time of the current study. Acute-phase
reactant proteins were negative in 8 patients, particularly in
patients with severe combined immunodeficiency (SCID) and
phagocytosis defects. Imaging findings on COVID-19 pulmo-
nary complications of PID patients varied from mild promi-
nence of bronchovascular markings to mucus plugging,
prebronchial thickening, diffuse patchy opacities, collapse/
consolidations, mosaic perfusion, and ground glass interstitial
disease, mirroring of the severity of diagnosed PID (Figs. S4–
S15).
Among the identified PID cases with COVID-19, 8 pa-
tients deceased (42.1%, Table 1) indicating a 10-folds higher
mortality rate in PID patients compared to the population
(0.003 vs. 0.0003, p < 0.001). Of note, the most lethal
COVID-19 infection among PID entities was observed in pa-
tients with SCID (0.03) and familial hemophagocytic
lymphohistiocytosis (FHL, 0.027). This notion confirms the
previous hypothesis that SARS-CoV-2 are more life-
threatening among patient with cellular immunodeficiency
and immune dysregulation with almost 150-folds higher risk
of mortality. All infected patients with less profound com-
bined immunodeficiencies, FHL, and autoinflammatory dis-
orders succumbed to COVID-infection. Monthly intravenous
immunoglobulin replacement therapy was continued during
the COVID-19 infection period in 12 patients, of which
66.6% recovered from the infection (4 deceased patients had
combined immunodeficiencies, Table 2).
Discussion
The current knowledge about COVID-19 in cases with under-
lying immunodeficiency is scarce [18–24]. Comparing to pre-
vious data reported mainly primary antibody deficient and
male patients with COVID-19 infection (Table S4), we did
not observe the dominancy of infected patients in this PID
category despite their high frequency among the national reg-
istry with no deceased patient. In the first observation in 7
cases from Italy, all were antibody-deficient patients with
14.2% mortality [25]. In another report from 582 children
and adolescents in Europe with PCR-confirmed SARS-CoV-
2 infection, 3 patients (0.5% of total cases) had a previously
diagnosed PID comprising common variable immunodefi-
ciency, congenital neutropenia, and Schimke immuno-
osseous dysplasia [26].
These data resembling the findings of the recent study by
Parri et al. [27] where they highlighted immunological com-
plications may underlie 7.4–12.5% of COVID-19 patients re-
ported from pediatric emergency departments. However, our
study may strengthen the current understanding of the impact
of the pandemic on all subgroups of PID and highlights the
requirement of tight measurements in children affected mainly
with combined immunodeficiency and immune dysregula-
tion. Of note, several recent studies identified that lymphope-
nia with prominent decreased T cell (mainly CD8+ cytotoxic T
cell) counts are associated with severe COVID-19 condition
and mortality [3, 28–31]. Indeed, lymphopenia seems to cor-
relate with the cytokine profile of the severe patients which
resemble our observation in PID patients [30, 32]. On the
other hand, the recent multinational cohort reported by ESID
(94 patients, 37%were with mild symptoms or asymptomatic,
9.5% mortality) revealed that older patients with combined
immunodeficiency (14 patients in this cohort all recovered,
Table S4) manifested milder presentations compared to our
patients, which may reflect different underlying diseases, but
also access to optimal treatment mainly HSCT [33].
While the induction of effective cellular immunity is likely
essential for the COVID-19 control, dysregulated T cell acti-
vation (by overproduction of IFN associated cytokines pro-
moting retention of lymphocytes in lymphoid organs) may
underly main immunopathology and contribute to disease se-
verity in COVID-19 patients [32, 34–36]. Although the expo-
sure to pathogens may be lower in PID patients due to more
strict self-isolation, it should be noted that the majority of PID
cases require to visit the hospital and medical centers regularly
which may predispose them even more to exposure to differ-
ent pathogens as well as COVID-19. Even though our ap-
proach between PID patients and the general population were
similarly based on decided national COVID-19 protocols
(RT-PCR test was performed in cases with a suggestive triad
of fever, cough, and dyspnea), it should be declared that some
infected cases from the population may be missed with this
inclusion criteria. Indeed, PID patients are followed-up more
regularly, whereas the infected immunocompetent individual
with mild infections in the normal population may not refer to
the medical centers. Therefore, future epidemiological studies
in other countries are required to evaluate this notion.
Our current genetic findings suggest a higher mortality rate
on special molecular defects associated with deficiency of the
IL-1 receptor (DIRA deficiency), STK4 deficiency (combined
immunodeficiency), and RAB27A deficiency (diseases of im-
mune dysregulation) with COVID-19. However, this data
need to be supported with future evidence from other PID
cohorts worldwide since these disorders are extremely rare.
The notion observed could alert physicians on whether the
usage of IL-1 inhibitors, such as anakinra, might be helpful
for the treatment of COVID-19, and this decision should be
made individually for each patient based on their genetic di-
agnosis and medical condition [37]. Although admission to
IL-1 inhibitor in intensive care unit admitted cases could sig-
nificantly reduce the mortality rate (hazard ratio of 0.22 com-
pared to non-receivers), this might only be indicated in pa-
tients with hemophagocytic lymphohistiocytosis, macrophage
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activation syndrome with certain overactivation of
inflammasome pathway. Of note, recent genetic analysis of
4 young brother pairs (range, 21–32 years) with respiratory
insufficiency due to severe COVID-19 suggested TLR7 defi-
ciency with reduced production of IFN-γ, a type II IFN as the
underlying cause [38].Moreover, review literature [25, 33, 38,
39, 40, 41] on PID patients with COVID-19 infections might
also indicate a possible association of the disease with muta-
tions in BTK (9 patients), IRF7 (7 patients) and TLR4 (4 pa-
tients), genes (Table S4). Although we did not identify
COVID-19 infection in any of our patients with innate im-
mune defects, this observation may also indicate future
follow-up on patients with defects in TLR and IFN pathways
are required to understand the genetic predisposition and path-
ogenesis of COVID-19 correctly, as 23 patients with disease-
causing variants and life-threatening COVID-19 have been
reported recently [39].
Our findings showed that about 30% of the total Iranian
population is younger than 20 years and indeed it has been
evident that they presented a very low frequency of COVID-
19 infections and almost no mortality compared to other age
categories (Fig. S1). Whereas about 57% of PID patients are
under the age of 20, and a significant number of COVID-19-
infected patients were observed in this age group, and the
majority of them died which indicates an obvious contrast to
the population. Moreover, in the total population, 70% are
over 20 years old comprising a considerable percentage of
patients with SARS-CoV-2 infection and the highest
COVID-19 mortality. In contrast, although about 43% of
PID patients are older than 20 years (1184 patients), only three
SARS-CoV-2 positive patients were recorded and none of
them had died due to SARS-CoV-2 which is again markedly
different from the normal population. We actually observed a
10-fold higher mortality rate and a reverse pattern of the age-
structure in COVID-19-infected PID patients compared to the
population. This is also indeed higher than the mortality rate
documented in children and adolescents in Europe where only
4 patients died, all older than 10 years, with a crude fatality
rate of 0.0069. Of note, one of those deceased patients (25%)
had underlying immunodeficiency due to HSCT [26]. But it is
important to highlight that recessive forms of PIDmight play a
role in the difference observed between our PID study and the
European pediatric cohort since these severe PIDs may possi-
bly increase the incidence of more severe COVID19 cases
during childhood.
Conclusion
Although COVID-19 is generally a mild disease in children
and adolescents (due to the lowACE2 receptor expression and
functional adaptive immunity) [42, 43], a fraction of them
including PID patients may develop severe disease requiring
intensive unit care admission and even fatal outcome. Future
studies may corroborate the individual risk of different PID
disorders and clarify the potential need for preemptive mea-
sures for specific subsets of PID patients at high risk of a
critical course of COVID19.
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